Mark Hahn

Mark Hahn

Director of Finance/CFO at VERONA PHARMA PLC

Net worth: 129 M $ as of 2024-03-30

61 year
Health Technology
Communications
Consumer Durables

Profile

Mark W.
Hahn
is an Independent Director at ALSP Orchid Acquisition Corp.
I and the Chief Financial Officer at Verona Pharma Plc.
He was previously the Chief Financial Officer at Charles & Colvard Ltd., Athenix Corp., Gigabeam Corp., BuildLinks, Inc., Cempra Pharmaceuticals, Inc., Cempra, Inc., and Dova Pharmaceuticals, Inc. He was also a Principal at Ernst & Young LLP and the Chief Financial Officer at Equitel, Inc. Hahn received his undergraduate degree from the University of Wisconsin-Milwaukee in 1984.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-01-31 64,268,512 ( 13.38% ) 129 M $ 2024-03-30

Mark Hahn active positions

CompaniesPositionStart
VERONA PHARMA PLC Director of Finance/CFO 2020-02-29
ALSP ORCHID ACQUISITION CORPORATION I Director/Board Member 2021-10-31
All active positions of Mark Hahn

Former positions of Mark Hahn

CompaniesPositionEnd
DOVA PHARMACEUTICALS, INC. Director of Finance/CFO 2019-11-11
Director of Finance/CFO 2017-11-29
Director of Finance/CFO 2017-10-31
Director of Finance/CFO 2008-12-31
GIGABEAM CORPORATION Director of Finance/CFO 2008-08-30
See the detail of Mark Hahn's experience

Training of Mark Hahn

University of Wisconsin-Milwaukee Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Hahn's experience

Connections

88

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
CHARLES & COLVARD, LTD.

Consumer Durables

VERONA PHARMA PLC

Health Technology

Private companies9

Communications

Commercial Services

Technology Services

Communications

Process Industries

Health Technology

Health Technology

Health Technology

Finance

See company connections